Johnson & Johnson CEO Apologizes For Defective Drug Recall
Posted on Oct 05, 2012
Following a large number of recalls involving children’s medications, the CEO of Johnson & Johnson, William Weldon, delivered an apology and an admission of guilt from a prepared statement given to the Committee on Oversight and Government Reform.
Weldon admitted that his company had not met their high standards of quality, that they had put out a poor product, that they had prevented children from accessing important medicines, and that they had tried to secretly buy back defective drugs from stores before issuing the recall.
Much of the committee hearing revolved around a phantom recall of Motrin medications in 2009 – a recall that Johnson & Johnson said it reported to the Food & Drug Administration (FDA) but that they later admitted was done secretly.
Weldon also announced that his company would once again begin selling some of the popular children’s products following the recall, which took place almost six months ago. The products, which will only be sold in limited quantities, include Children’s Tylenol and Children’s Liquid Tylenol. The products will not be manufactured in the United States – which factories have been shut down twice in recent years for violating federal regulations – but will rather be made in a Canadian facility. In addition, Johnson & Johnson plans to spend $100 million improving the quality and safety at their plants.
Weldon was adamant that his company learns the hard lessons from the 2010 defective drug recalls and that similar happenings will never again happen in the future.